ONCT - Oncternal trades higher on updated results from clinical trial for Ewing sarcoma

Oncternal Therapeutics (ONCT) added ~9.3% in the premarket after the company disclosed updated interim results from a Phase 1/2 clinical trial evaluating TK216 in patients with relapsed or refractory Ewing sarcoma.The data is contained in an abstract that will be part of an oral presentation scheduled at the American Society of Clinical Oncology ((ASCO)) 2021 Annual Meeting.As of the April 16, 2021 data cut-off date, 68 patients with relapsed or refractory Ewing sarcoma were treated with TK216 in study TK216-01, an ongoing study designed to evaluate TK216 as a single agent and in combination with vincristine (anti-cancer chemotherapy).At RP2D: the objective response rate ((ORR)) was 9.7% (3 of 31 evaluable patients) with one patient with an unconfirmed partial response ((PR)).11 had (35.5%) stable disease ((SD)), for a disease control rate (CR, PR, SD) of 45.2% (14 of 31 evaluable patients).Enrollment of patients is underway in a Phase 2 expansion cohort.Notably, after two cycles of therapy, two

For further details see:

Oncternal trades higher on updated results from clinical trial for Ewing sarcoma